● Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Condition: Low Grade Serous Ovarian Cancer · Sponsor: Verastem, Inc.

PhasePhase 3

Planned participants270

Who can joinFemale, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Verastem Call Center · 781-292-4204 · RAMP301TrialSupport@verastem.com

Always discuss trial participation with your own doctor first.

Locations (106)

HonorHealth	Phoenix, Arizona, United States	Recruiting
University of Arkansas	Little Rock, Arkansas, United States	Recruiting
UCLA Health	Los Angeles, California, United States	Recruiting
UC Davis	Sacramento, California, United States	Recruiting
University of California, San Francisco	San Francisco, California, United States	Recruiting
Yale University	New Haven, Connecticut, United States	Recruiting
Florida Cancer Specialists - South	Fort Myers, Florida, United States	Recruiting
Mount Sinai	Miami Beach, Florida, United States	Recruiting
AdventHealth	Orlando, Florida, United States	Recruiting
Moffitt Cancer Center	Tampa, Florida, United States	Recruiting
Florida Cancer Specialists Research East	West Palm Beach, Florida, United States	Recruiting
Winship Cancer Institute at Emory University	Atlanta, Georgia, United States	Recruiting

+ 94 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06072781